Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing

Journal of Immunology

Volumn 163, Issue 3, 1999, Pages 1246-1252

  Zeidler, Reinhard ^a   Reisbach, Gilbert ^b   Wollenberg, Barbara ^a   Lang, Stephan ^a   Chaubal, Sarita ^a   Schmitt, Bärbel ^a   Lindhofer, Horst ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Gesell F Umweltforschung P   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CYTOKINE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 1 DERIVATIVE; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6;

ACCESSORY CELL; ANIMAL CELL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; RATS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033178740     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Inaba, K., and R. M. Steinman. 1984. Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release. J. Exp. Med. 160:1717.
2. Stüber, E., W. Strober, and M. Neurath. 1996. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through inhibition of interleukin 12 secretion. J. Exp. Med. 183:693.
3. Janeway, C. A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76:275.
4. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy. Science 248:1349.
5. Fanger, M. W., D. M. Segal, and J. R. Wunderlich. 1990. Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J. 4:2846.
6. Weiner, L. M., J. I. Clark, D. B. Ring, and R. K. Alpaugh. 1995. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and FcγRIII. J. Hematother. 4:453.
7. Valerius, T., B. Stockmeyer, A. vam Spriel, R. Graziano, I. van den Herik-Oudijk, R. Repp, Y. Deo, J. Lund, J. Kalden, M. Gramatzki, and J. G. J. van de Winkel. 1997. FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90:4485.
8. Klein, S. C., L. H. Boer, R. A. De Weger, G. C. De Gast, and E. J. E. G. Bast. 1997. Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3 × CD19. Scand. J. Immunol. 46:452.
9. Lindhofer, H., R. Mocikat, B. Steipe, and S. Thierfelder. 1995. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155:219.
10. Heo, D. S., J. G. Park, K. Hata, R. Day, R. B. Herberman, and T. L. Whiteside. 1990. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res. 50:3681.
11. Litvinov, S. V., M. P. Velders, H. A. Bakker, G. J. Fleuren, and S. O. Warnaar. 1994. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125:437.
12. Haagen, I. A., A. J. Geerars, M. R. Clark, and J. G. van de Winkel. 1995. Interaction of human monocyte Fcγ receptors with rat IgG2b: a new indicator for the FcγRIIa (R-H131) polymorphism. J. Immunol. 154:1852.
13. Sacchi, M., C. H. Snyderman, D. S. Heo, J. T. Johnson, F. d'Amico, R. B. Herberman, and T. L. Whiteside. 1990. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated cells and interleukin-2. Cancer Res. 50:3113.
14. Koch, W. M., and W. J. Richtsmeier. 1989. Lysis of squamous cell carcinoma via antibody-dependent cellular cytotoxicity. Arch. Otolaryngol. Head Neck Surg. 115:669.
15. Fanger, N. A., K. Wardwell, L. Shen, T. F. Tedder, and P. M. Guyre. 1996. Type I (CD64) and type II (CD32) Fcγ receptor-mediated phagocytosis by human blood dendritic cells. J. Immunol. 157:541.
16. Riethmüller, G., E. Schneider Gadicke, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, H. Pichlmaier, H. Hirche, R. Pichlmayr, et al. 1994. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 343:1177.
17. Riethmüller, G., E. Holz, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, I. Funke, H. Pichlmaier, H. Hirche, et al. 1998. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16:1788.
18. + lymphocyte clones. J. Immunol. 158:5612.
19. Shu, U., M. Kiniwa, C. Y. Wu, C. Maliszewski, N. Vezzio, J. Hakimi, M. Gately, and G. Delespesse. 1995. Activated T cells induce interleukin-12 production by monocytes via CD40-CD40 ligand interaction. Eur. J. Immunol. 25:1125.
20. Tsung, K., J. B. Meko, G. R. Peplinski, Y. L. Tsung, and J. A. Norton. 1997. IL-12 induces T helper 1-directed antitumor response. J. Immunol. 158:3359.
21. Van Gool, S. W., P. Vandenberghe, M. de Boer, and J. L. Ceuppens. 1996. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol. Rev. 153:47.
22. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
23. McLellan, A. D., R. V. Sorg, L. A. Williams, and D. N. Hart. 1996. Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur. J. Immunol. 26:1204.
24. Adema, G. J., F. Hartgers, R. Verstraten, E. de Vries, G. Marland, S. Menon, J. Foster, Y. Xu, P. Nooyen, T. McClanahan, et al. 1997. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387:713.
25. Cella, M., D. Scheidegger, K. Palmer Lehmann, P. Lane, A. Lanzavecchia, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
26. de Gast, G. C., I. A. Haagen, A. A. van Houten, S. C. Klein, A. J. Duits, R. A. de Weger, T. M. Vroom, M. R. Clark, J. Phillips, A. J. van Dijk, et al. 1995. CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 40:390.
27. Clynes, R., Y. Tekechi, Y. Moroi, A. Houghton, and J. V. Ravetch. 1998. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95:652.
28. Daniel, P. T., A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dörken, and A. Pezzutto. 1998. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 92:4750.
29. Weiner, G. J., and J. R. Hillstrom. 1991. Bispecific anti-idiotype/anti-CD3 anti-body therapy of murine B cell lymphoma. J. Immunol. 147:4035.
30. Renner, C., W. Jung, U. Sahin, R. Denfeld, C. Pohl, L. Trümper, F. Hartmann, D. V., R. van Lier, and M. Pfreundschuh. 1994. Cure of xenografted human tumors by bispecific antibodies and human T cells. Science 264:833.
31. Lindhofer, H., H. Menzel, W. Günther, L. Hültner, and S. Thierfelder. 1996. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 88:4651.
32. Bohlen, H., O. Manzke, S. Titzer, J. Lorenzen, D. Kube, A. Engert, H. Abken, J. Wolf, V. Diehl, and H. Tesch. 1997. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3 × CD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells. Cancer Res. 57:1704.
33. Weiner, G. J., S. A. Kostelny, J. R. Hillstrom, M. S. Cole, B. K. Link, S. L. Wang, and J. Y. Tso. 1994. The role of T cell activation in anti-CD3 × antitumor bispecific antibody therapy. J. Immunol. 152:2385.
34. Mocikat, R., D. Selmayr, S. Thierfelder, and H. Lindhofer. 1997. Trioma-based vaccination against B cell lymphona confers long-lasting tumor immunity. Cancer Res. 57:2346.
35. Quak, J. J., G. Van Dongen, J. G. Brakkee, D. J. Hayashida, A. J. Balm, G. B. Snow, and C. J. Meijer. 1990. Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17-1A antigen. Hybridoma 9:377.
36. Bjork, P., U. Jonsson, H. Svedberg, K. Larsson, P. Lind, J. Dillner, G. Hedlund, M. Dohlsten, and T. Kalland. 1993. Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J. Biol. Chem. 268:24232.